GAMMA Investing LLC Acquires 411 Shares of Natera, Inc. $NTRA

GAMMA Investing LLC lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 48.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,259 shares of the medical research company’s stock after purchasing an additional 411 shares during the quarter. GAMMA Investing LLC’s holdings in Natera were worth $213,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. HighPoint Advisor Group LLC increased its stake in Natera by 30.8% in the first quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company’s stock valued at $308,000 after acquiring an additional 468 shares during the last quarter. Amalgamated Bank increased its stake in Natera by 9.8% in the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company’s stock valued at $1,173,000 after acquiring an additional 740 shares during the last quarter. Park Avenue Securities LLC bought a new position in Natera in the second quarter valued at approximately $1,525,000. Comerica Bank increased its stake in Natera by 24.1% in the first quarter. Comerica Bank now owns 141,106 shares of the medical research company’s stock valued at $19,954,000 after acquiring an additional 27,379 shares during the last quarter. Finally, Asset Management One Co. Ltd. bought a new position in Natera in the first quarter valued at approximately $6,753,000. 99.90% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Stephens reissued an “overweight” rating and issued a $183.00 price objective on shares of Natera in a research note on Friday, August 15th. Piper Sandler reissued an “overweight” rating and issued a $220.00 price objective (up from $210.00) on shares of Natera in a research note on Monday, August 11th. Wells Fargo & Company assumed coverage on shares of Natera in a research note on Monday, September 22nd. They issued an “equal weight” rating and a $175.00 price objective on the stock. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Finally, Morgan Stanley restated an “overweight” rating and issued a $195.00 target price on shares of Natera in a research report on Sunday, August 10th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $192.88.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $162.97 on Monday. The firm has a market cap of $22.37 billion, a PE ratio of -85.32 and a beta of 1.68. The firm’s fifty day moving average is $158.87 and its 200-day moving average is $156.18. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $183.00.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The business had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.Natera’s revenue for the quarter was up 32.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity at Natera

In other news, Director Rowan E. Chapman sold 2,750 shares of Natera stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total transaction of $459,222.50. Following the transaction, the director owned 6,015 shares in the company, valued at approximately $1,004,444.85. The trade was a 31.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Burkes Brophy sold 3,045 shares of the business’s stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total transaction of $418,383.00. Following the completion of the transaction, the chief financial officer owned 65,430 shares in the company, valued at approximately $8,990,082. The trade was a 4.45% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,423 shares of company stock valued at $8,459,656 in the last quarter. Insiders own 5.63% of the company’s stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.